• DMXAA (Vadimezan): A Paradigm Shift in Tumor Endothelial ...

  2025-10-01

  Discover how DMXAA (Vadimezan, AS-1404) redefines vascular disruption and immune signaling in cancer research. This in-depth analysis unveils novel insights into endothelial STING-JAK1 dynamics and next-generation applications in tumor microenvironment modulation.

• Redefining Tumor Vasculature Disruption: DMXAA (Vadimezan...

  2025-09-30

  This thought-leadership article explores the transformative potential of DMXAA (Vadimezan, AS-1404)—a vascular disrupting agent (VDA)—in the evolving landscape of cancer biology. Integrating mechanistic insights from recent breakthroughs in endothelial immunity, including the pivotal STING-JAK1 axis, we provide strategic guidance for translational researchers aiming to leverage DMXAA’s dual action on tumor vasculature and immune modulation. Unlike standard product summaries, this article offers a forward-thinking synthesis of experimental validation, competitive context, and clinical relevance, while linking to authoritative resources for deeper exploration.

• DMXAA (Vadimezan): Integrative Insights into Tumor Vascul...

  2025-09-29

  Explore how DMXAA (Vadimezan, AS-1404), a vascular disrupting agent for cancer research, intersects with endothelial immunity and the STING-JAK1 axis. This article uniquely examines DMXAA’s mechanistic role in tumor vasculature disruption and immune modulation, offering advanced perspectives for cancer biology research.

• DMXAA (Vadimezan): Integrative Modulation of Tumor Vascul...

  2025-09-28

  Explore how DMXAA (Vadimezan, AS-1404) redefines cancer research as a vascular disrupting agent by bridging tumor vasculature disruption with advanced immunomodulatory signaling. This article uniquely integrates STING-JAK1 insights and mechanistic depth for transformative cancer biology research.

• DMXAA (Vadimezan): Integrating Vascular Disruption with I...

  2025-09-27

  Explore how DMXAA (Vadimezan, AS-1404) uniquely bridges vascular disruption and immune modulation in cancer biology research. This article delivers a comprehensive, mechanistic perspective on DMXAA’s dual action as a vascular disrupting agent and immune pathway modulator, offering new insights beyond traditional anti-angiogenic strategies.

• DMXAA (Vadimezan): Integrating Tumor Vasculature Disrupti...

  2025-09-26

  Explore how DMXAA (Vadimezan, AS-1404) bridges vascular disruption and immune modulation for cancer biology research. This in-depth analysis highlights novel mechanisms and translational strategies that set DMXAA apart from traditional anti-angiogenic agents.

• Adenosine Triphosphate (ATP): From Energy Carrier to Mast...

  2025-09-25

  Explore how Adenosine Triphosphate (ATP) operates beyond its classic role as a universal energy carrier, acting as a dynamic regulator of mitochondrial enzyme turnover and metabolic reprogramming. This article provides an advanced scientific perspective on ATP's multifaceted mechanisms in cellular metabolism research.

• WY-14643 (Pirinixic Acid): Unraveling PPARα Signaling in ...

  2025-09-24

  Explore how WY-14643 (Pirinixic Acid), a potent PPARα agonist, uniquely modulates the tumor microenvironment and metabolic signaling beyond classic lipid regulation. This article unveils novel mechanistic insights and advanced research applications, setting itself apart in the landscape of metabolic disorder research.

• ABT-737: Mechanistic Insights into BCL-2 Inhibition and M...

  2025-09-23

  Explore the mechanistic underpinnings of ABT-737, a potent BH3 mimetic BCL-2 protein inhibitor, and its role in inducing apoptosis via the intrinsic mitochondrial pathway. This article synthesizes recent advances in mitochondrial signaling and cell death, providing actionable insights for cancer research.

• Polycyclic aromatic hydrocarbons PAHs are abundant environme

  2025-03-03

  

  Polycyclic aromatic hydrocarbons (PAHs) are abundant environmental contaminants that are produced by the incomplete combustion of organic matter, combustion engines, residential heating, ConA glycoprotein purification burning, and industrial activities (Gelboin, 1980; Phillips, 1999, Phillips, 2002

• The inflammatory cytokine IL is an additional factor that

  2025-03-03

  

  The inflammatory cytokine IL-6 is an additional factor that has been hypothesized to contribute to epinephrine-mediated repression of drug detoxifying proteins such as CYP3A4 (Aninat et al., 2008). Indeed, this CYP is well-known to be repressed by IL-6 (Dickmann et al., 2011) and epinephrine has pre

• br Conflict of interest br

  2025-03-03

  

  Conflict of interest Financial support Acknowledgments This work was supported by the Japanese Millennium project. We thank all members of the Center for Genomic Medicine of RIKEN and Dainippon-Sumitomo Pharma Co., Ltd. for supporting this study. We are also grateful to members of the Hiros

• br Improvement of endothelial function The vascular endothel

  2025-03-03

  

  Improvement of endothelial function The vascular endothelium is a single layer of Senexin A sale that lines the inner surface of all blood vessels and the heart. In addition to function as a selective barrier to prevent the diffusion of macromolecules from the blood lumen to the intestinal space

• br Conclusion br Acknowledgments This research

  2025-03-03

  

  Conclusion Acknowledgments This research has been supported by the Ratchadaphiseksomphot Endowment Fund 2013 of Chulalongkorn University (CU-56-341-AS) and the Ratchadapiseksompotch Fund (RA55/22), Faculty of Medicine, Chulalongkorn University. The authors commemorate the 100th Anniversary of

• Somatostatin analogs also bind to somatostatin

  2025-03-01

  

  Somatostatin analogs also bind to somatostatin receptors. It has been reported that octreotide has a high affinity for hSSTR2, moderate affinity for hSSTR3 and hSSTR5, and does not bind to hSSTR1 or hSSTR4 (Ben-Shlomo and Melmed 2008). Compared to octreotide, pasireotide displays 40-, 30-, and 5-fol

16195 records 2/1080 page Previous Next 12345 下5页 Last page